De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ViewRay Beheer

Beheer criteriumcontroles 1/4

De CEO ViewRay's is Paul Ziegler, benoemd in Jul2023, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.039% van de aandelen van het bedrijf, ter waarde $ 7.19. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.7 jaar en 3.5 jaar.

Belangrijke informatie

Paul Ziegler

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	3.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Paul Ziegler's beloning veranderd ten opzichte van ViewRay's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2023	n/a	n/a	-US$110m
Dec 31 2022	n/a	n/a	-US$107m
Sep 30 2022	n/a	n/a	-US$107m
Jun 30 2022	n/a	n/a	-US$106m
Mar 31 2022	n/a	n/a	-US$109m
Dec 31 2021	US$2m	US$350k	-US$110m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Paul redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Paul te vergelijken met de prestaties van het bedrijf.

CEO

Paul Ziegler (50 yo)

less than a year

Tenure

US$2,028,555

Compensatie

Mr. Paul Ziegler. Jr., J.D., serves as President, Chief Executive Officer and Director at ViewRay, Inc. since July 2023 and was its Chief Commercial Officer since 2021 until July 2023 and served as its Exe...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Ziegler	President	less than a year	US$2.03m	0.039% $ 7.2
James Dempsey	Founder & Chief Scientific Officer	19.6yrs	US$1.17m	0.16% $ 29.9
Jacob Signoriello	Interim Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Drew Hill	Senior Vice President of Operations & Development	1.8yrs	geen gegevens	geen gegevens
Matt Harrison	Director of Investor Relations	no data	geen gegevens	geen gegevens
Sanket Shah	Senior VP & General Counsel	less than a year	geen gegevens	0.21% $ 38.6
Karen Hackstaff	Vice President of Marketing	no data	geen gegevens	geen gegevens
Julianne Mast	Vice President of Human Resources	less than a year	geen gegevens	geen gegevens
Martin Fuss	Chief Medical Officer	no data	geen gegevens	geen gegevens
Adam Podbelski	Senior Vice President of Commercial Operations	1.8yrs	geen gegevens	0.24% $ 44.7
Steven Annen	Senior Vice President of Global Marketing	less than a year	geen gegevens	geen gegevens
Ashley Kluth	Senior Manager of Investor Relations	no data	geen gegevens	geen gegevens

0.7yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VRAY.Q wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Ziegler	President	less than a year	US$2.03m	0.039% $ 7.2
Caley Castelein	Independent Director	15.8yrs	US$212.17k	0.027% $ 5.0
B. Johnson	Independent Director	3.5yrs	US$208.00k	0.092% $ 16.8
Brian Roberts	Independent Director	7.8yrs	US$221.00k	0.065% $ 12.0
Daniel Moore	Independent Chairman	5.7yrs	US$261.00k	0.11% $ 20.0
Scott Drake	Director	5.3yrs	US$5.80m	0.32% $ 59.3
Karen Prange	Independent Director	2.3yrs	US$201.00k	0% $ 0
Stefanie Corradini	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Enis Ozyar	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
James Good	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Lauren Henke	Member of Medical Advisory Board	less than a year	geen gegevens	geen gegevens
Rupesh Kotecha	Member of Medical Advisory Board	less than a year	geen gegevens	geen gegevens

3.5yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VRAY.Q wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

ViewRay Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces CFO Changes

Insider recently bought US$117k worth of stock

President recently bought US$400k worth of stock

Recent updates

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Consensus revenue estimates decrease by 16%

ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023

Market Cool On ViewRay, Inc.'s (NASDAQ:VRAY) Revenues Pushing Shares 63% Lower

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial

ViewRay, Inc. Announces CFO Changes

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$117k worth of stock

ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022

ViewRay MRI-guided radiation therapy selected by SUNY upstate cancer center

ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients

ViewRay's MRI-guided radiation therapy gets approval in China

ViewRay MRI-guided radiation therapy selected by VA Houston Healthcare System

ViewRay, Inc. Selects Denver for Headquarters

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viewray, Inc. Updates Earnings Guidance for the Year 2022

ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022

ViewRay: Insider Buying In This $3 Stock

Consensus estimates of losses per share improve by 11%

President recently bought US$400k worth of stock

Price target decreased to US$7.43

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022

ViewRay, Inc., Annual General Meeting, Jun 10, 2022

ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$96k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Viewray, Inc. Provides Revenue Guidance for the Year 2022

ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Chief Financial Officer recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 3Q 2020)

Chief Financial Officer recently bought US$213k worth of stock

Price target increased to US$8.03

Is ViewRay (NASDAQ:VRAY) Using Debt Sensibly?

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)

ViewRay, Inc.(NasdaqGM:VRAY) dropped from Russell Microcap Value Index

ViewRay, Inc. Not to Provide Financial Guidance

ViewRay, Inc. 2021 Q1 - Results - Earnings Call Presentation

Price target increased to US$6.32

Chief Operating Officer has left the company

ViewRay, Inc. Announces the Resignation of Shahriar Matin as Chief Operating Officer, Effective from March 31, 2021

Full year 2020 earnings released: US$0.73 loss per share (vs US$1.18 loss in FY 2019)

Revenue beats expectations

Read This Before Selling ViewRay, Inc. (NASDAQ:VRAY) Shares

ViewRay, Inc. to Report Q4, 2020 Results on Mar 04, 2021

ViewRay, Inc. Announces Retirement of D. Keith Grossman from Board of Directors

Viewray, Inc. Appoints Phil Spencer to Its Board of Directors

Edogawa Hospital in Tokyo Installs Japan's First ViewRay MRIdian Linac

The Henry Ford Cancer Institute Installs Its Second Viewray Mridian® Linac

How Many ViewRay, Inc. (NASDAQ:VRAY) Shares Do Institutions Own?